Physician profile
Samer Schuman
NPI 1588875009
$2,644.99
in general payments reported to CMS, 2019-2025
11 companies · $44.21 in 2025
The $44.21 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $2,157 · 2021: $30.51 · 2022: $56.66 · 2023: $149 · 2024: $60.66 · 2025: $44.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,082.93 | 2019-2023 | Zejula, Jemperli |
| Allergan, INC. | $127.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $99.64 | 2019-2024 | Lynparza |
| Abbvie INC. | $74.27 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Genmab U.S., INC. | $60.39 | 2023 | Tivdak |
| Tesaro, INC. | $48.94 | 2019 | |
| Immunogen, INC. | $45.56 | 2023 | Elahere |
| Merck Sharp & Dohme LLC | $43.31 | 2020 | |
| Medical Device Business Services, INC. | $30.54 | 2022 | |
| Daiichi Sankyo INC. | $17.67 | 2024 | Enhertu |
| Intuitive Surgical, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Schuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.